$0.00
Ippei Kanazawa and Toru Yamaguchi (Editors)
Shimane University, Japan
Series: Neurology – Laboratory and Clinical Research Developments
BISAC: MED056000
Although bone mineral density (BMD) is considered as a gold standard for evaluating fracture risk in non-diabetic osteoporosis, accumulative evidence shows that patients with type 2 diabetes have high fracture rate in spite of the absence of BMD reduction, indicating that BMD is not sensitive enough to assess the risk of osteoporotic fractures in them. In addition, hyperglycemia itself is not associated with BMD or fracture risk, either. Therefore, the etiology of diabetes-related bone fragility and its diagnostic markers replacing BMD need to be explored. This new book discusses how serum adiponectin level was associated with serum osteocalcin in patients with type 2 diabetes in clinical studies (Imprint: Nova Biomedical)
Table of Contents
Abstract
Introduction
Advanced Glycation End Products (AGEs) and Bone Metabolism in Type 2 Diabetes
Insulin-Like Growth Factor-I (IGF-I) and Bone Metabolism in Type 2 Diabetes
Adiponectin and Bone Metabolism in Type 2 Diabetes
Relationships between Bone and Glucose Metabolism through the Action of Osteocalcin and Adiponectin
Conclusion
References
Index
We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!
